Ligand Pharmaceuticals Inc
LGND- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000886163
In the last 90 days, Ligand Pharmaceuticals Inc insiders filed 0 open-market purchases and 8 sales; 420 institutions reported holding it in 13F filings for Q2 2026, worth $7.15B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $6.34B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $17.0M in total
- 8
- 13F holdersQ2 2026, +62 vs. previous quarter
- 420
- 13F valueReported value at the end of Q2 2026
- $7.15B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $268.1M
- +60.4% year over year
- Net income, FY2025
- $124.5M
- No comparable prior period
- Free cash flow, FY2025
- $48.9M
- −48.6% year over year
- Revenue, Q3 FY2026
- $78.7M
- −31.8% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.46M
- Shares sold short
- Change
- −37.8K
- −1.5% vs. previous
- Days to cover
- 10.53
- At average daily volume
Superinvestors holding LGND, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding LGND at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Ligand Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 6, 2026 (view filing)5:41 PM ET | Nov 4 | 2 days | Aryeh JasonDirector | SSale | −282 | $319.99 | −$90.2K | −0.3%108.5K after | |
| Nov 4, 2026 (view filing)4:23 PM ET | Nov 2 | 2 days | Reardon AndrewCLO & Secretary | SSale | −5.00K | $313.22 | −$1.57M | −13.6%31.9K after | 13 lots10b5-1 |
| Nov 3, 2026 (view filing)7:39 PM ET | Oct 30-Nov 2 | 4 days | Aryeh JasonDirector | SSale | −2.11K | $320.30 | −$676.2K | −1.9%108.8K after | 6 lots |
| Oct 6, 2026 (view filing)4:35 PM ET | Oct 2 | 4 days | Reardon AndrewCLO & Secretary | SSale | −5.00K | $304.07 | −$1.52M | −13.6%31.9K after | 6 lots10b5-1 |
| Sep 14, 2026 (view filing)4:59 PM ET | Sep 10 | 4 days | Zimmermann MartineDirector | SSale | −1.20K | $285.00 | −$342.0K | −23.5%3.90K after | |
| Sep 8, 2026 (view filing)6:34 PM ET | Sep 3 | 5 days | Reardon AndrewCLO & Secretary | SSale | −5.00K | $286.09 | −$1.43M | −12.0%36.5K after | 5 lots10b5-1 |
| Aug 14, 2026 (view filing)5:05 PM ET | Aug 12 | 2 days | Espinoza OctavioChief Financial Officer | SSale | −31.6K | $292.07 | −$9.24M | −53.3%27.7K after | 10b5-1 |
| Aug 14, 2026 (view filing)5:04 PM ET | Aug 12 | 2 days | Haas JasonDirector | SSale | −7.14K | $292.81 | −$2.09M | −64.2%3.98K after | |
| Aug 4, 2026 (view filing)6:42 PM ET | Aug 3 | 1 day | Reardon AndrewCLO & Secretary | SSale | −5.00K | $288.99 | −$1.44M | −10.7%41.5K after | 10 lots10b5-1 |
| Jul 6, 2026 (view filing)5:11 PM ET | Jul 1 | 5 days | Reardon AndrewCLO & Secretary | SSale | −5.00K | $313.28 | −$1.57M | −10.7%41.5K after | 8 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 420 holdersThe largest institutional positions in Ligand Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3,100,996 | $980.2M | 0.01% | +139,073+4.7% | Added |
| Invesco Ltd. | 1,201,644 | $379.8M | 0.03% | +378,040+45.9% | Added |
| Vanguard Portfolio Management LLC | 1,138,316 | $359.8M | 0.02% | +38,049+3.5% | Added |
| Jupiter Topco LLC | 1,040,578 | $328.9M | 0.13% | +1,040,578 | New |
| Vanguard Capital Management LLC | 870,950 | $275.3M | 0.01% | +22,861+2.7% | Added |
| State Street Corp | 826,539 | $261.3M | 0.01% | +47,683+6.1% | Added |
| FMR LLC | 762,827 | $241.1M | 0.01% | +166,700+28.0% | Added |
| Franklin Resources Inc | 752,044 | $237.7M | 0.05% | +178,867+31.2% | Added |
| Congress Asset Management Co | 659,911 | $208.6M | 1.29% | +155,274+30.8% | Added |
| Geode Capital Management, LLC | 589,020 | $186.2M | 0.01% | +30,086+5.4% | Added |
Holders of 5% or more of LGND
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Ligand Pharmaceuticals Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 14.50%2.84M shares | −1.10 ppfrom 15.60% | Feb 5, 20252 filings | Oct 17, 2025 | SEC |
| Invesco Ltd. | 13G/A | 7.60%1.52M shares | +1.50 ppfrom 6.10% | Aug 13, 20262 filings | Nov 10, 2026 | SEC |
| Vanguard Portfolio Management LLC | 13G | 5.56%1.11M shares | New | May 1, 20261 filing | May 1, 2026 | SEC |
| Janus Henderson Group PLC | 13G/A | 5.30%1.04M shares | −0.20 ppfrom 5.50% | Feb 11, 20219 filings | Nov 14, 2025 | SEC |
| Vanguard Capital Management LLC | 13G | 5.00%997.6K shares | New | May 1, 20261 filing | May 1, 2026 | SEC |
Politician trades
All politician trades in LGND2 members of Congress reported 8 trades in Ligand Pharmaceuticals Inc since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Jun 8, 2026 |  Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Apr 7, 2026 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Feb 13, 2026 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Feb 13, 2026 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Dec 3, 2020 |  Katherine M. Clark House · MA | Sell | $1K-$15K |
House · CA · Jun 8, 2026
Buy$1K-$15K
House · CA · Apr 7, 2026
Buy$1K-$15K
House · CA · Feb 13, 2026
Buy$1K-$15K
House · CA · Feb 13, 2026
Buy$1K-$15K
House · MA · Dec 3, 2020
Sell$1K-$15K